TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05172843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical knee arthroplasty
Description: Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised weight loss
Description: The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51.
Study: NCT05200676

Intervention type: DEVICE
Intervention: SmartPill
Description: SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
Study: NCT05750576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated dressings
Description: Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
Study: NCT05750576

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non impregnated dressings
Description: Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
Study: NCT05490576

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F] PI-2620 Tau Ligand
Description: Tau binding ligand
Study: NCT06012786

Intervention type: DIAGNOSTIC_TEST
Intervention: VAS
Description: Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
Study: NCT04872595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized rATG (P-rATG)
Description: P-rATG days (always starting on Day -12 to -10)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized rATG (P-rATG)
Description: P-rATG days (always starting on Day -12 to -10)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyper fractionated total body irradiation
Description: (1375 - 1500cGy\*) Day -9 to -6~\*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: (5mg/kg/day x 2 day) Day -5 to -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: (60mg/kg/day x 2 days) Day -3 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Day +7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Day +7
Study: NCT06012786

Intervention type: DIAGNOSTIC_TEST
Intervention: Quick DASH
Description: The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
Study: NCT04872595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg\*h/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: (70mg/m2/day x 2 days) Day -6 to -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: (25mg/m2/day x 5 days) Day -6 to -2
Study: NCT06012786

Intervention type: DIAGNOSTIC_TEST
Intervention: Quick DASH
Description: The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lymqol-Arm
Description: Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lymqol-Arm
Description: Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.

Intervention type: DIAGNOSTIC_TEST
Intervention: Range of Motion of Shoulde Joint
Description: Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Range of Motion of Shoulde Joint
Description: Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
Study: NCT05642702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide
Description: Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptide complexed HA Age Defying Gel with Natural Extracts
Description: Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts
Description: Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1% w/v Sodium Lauryl Sulphate (SLS) solution
Description: 1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v
Description: A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
Study: NCT05527444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg/ml
Description: Secukinumab 150 mg will be administered at Baseline, Week 1, 2, 3, 4, 6, 8 followed by dosing every 4 weeks until Week 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg/ml
Description: Secukinumab 150 mg will be administered at Baseline, Week 1, 2, 3, 4, 6, 8 followed by dosing every 4 weeks until Week 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Ab
Description: adalimumab biosimilar 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Ab
Description: adalimumab biosimilar 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Pill
Description: If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Pill
Description: If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Pill
Description: If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Pill
Description: If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.
Study: NCT05426070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training-based exercise
Description: Participants will take part in two group-based Zoom exercise sessions and two individual exercise sessions per week for three months. Exercise sessions will include a combination of various aerobic (e.g., jogging in place, high knees) and muscle strengthening exercises (e.g., burpees, push-ups, lunges, body weight squats) designed to keep heart rate in the 60-85% range of maximum heart rate. Participants will choose from a variety of options for their two individual sessions (e.g., online exercise video, jogging or walking outside, prescribed exercise session listed on the website, or any other exercise) and modifications for each exercise will be made depending on the participant's ability and current fitness and strength level. Participants will be instructed to stop exercising if problems occur and will receive training and handouts on how to recognize problems such as angina and myocardial infarction.
Study: NCT04770038

Intervention type: BEHAVIORAL
Intervention: Dialectical Behavior Therapy (DBT)
Description: Evidence-based psychotherapy for the treatment of Borderline Personality Disorder
Study: NCT05719363

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inogen Rove 6 Portable Oxygen Concentrator
Description: The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inogen Rove 6 Portable Oxygen Concentrator
Description: The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient.
Study: NCT06034509

Intervention type: OTHER
Intervention: No intervention. This is an observational study.
Description: There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.

Intervention type: OTHER
Intervention: No intervention. This is an observational study.
Description: There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.

Intervention type: OTHER
Intervention: No intervention. This is an observational study.
Description: There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.
Study: NCT06311890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-chlorin e6 triglumine
Description: a photodynamic therapy with chlorin-e6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acne removal surgery
Description: acne removal surgery will be given before red light exposure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: acne removal surgery
Description: acne removal surgery will be given before red light exposure
Study: NCT05595993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Study participants will be allocated to receive oral administration of 200 mg cilostazol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be allocated to receive oral administration of placebo.
Study: NCT06452940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 16-week clinical pilates exercise program will be applied 3 days a week for 60 minutes each session. It will consist of a warm-up, main exercise and a cool-down period.Exercises will start with 10 repetitions and will be gradually increased in 3-week periods.
Study: NCT05357222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Straw phontion
Description: Pitch Glides: (1 minute) Vocalize through the straw starting from as low as possible to as high as possible. As the participant you will want to get as much as your vocal range as possible. But, don't let the voice get growly at the bottom or press it into a painful range at the top.~2. Accents: (1 minute) Vocalize progressive little hills or accents. It sounds like a revving engine of the car.~3. Song: (1 minute) Pick a favorite song and vocalize it through the straw. Examples: National Anthem, Happy Birthday, Mary had a Little Lamb. These are great songs because they have a range of pitches and one can build some accents in, as well.~4. Reading passage: (1 minute) Vocalize a reading passage through the straw. Be as dramatic as possible, using a lot of inflection.
Study: NCT06409143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tES
Description: The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tES
Description: The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tES
Description: The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tES
Description: The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UE rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
Study: NCT05360134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carica Papaya Leaf Extract
Description: Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in a similar manner
Study: NCT06409143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UE rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
Study: NCT05601167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir/ritonavir
Description: Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days
Study: NCT06409143

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: UE rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tES (Bilateral)
Description: The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds.
Study: NCT05005390

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTIP ventilation
Description: In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTIP ventilation
Description: In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask Ventilation
Description: In mask ventilation, a mask is placed over the nose and mouth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask Ventilation
Description: In mask ventilation, a mask is placed over the nose and mouth.
Study: NCT04871295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight
Description: Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
Study: NCT06344819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves insertion of thin filiform needles (gauze 30-40) at certain points on the body.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: During sham acupuncture, the point on the participant's thigh 6 inches proximal to the ST36 acupuncture point is gently tapped with an acupuncture needle guide tube and an acupuncture needle is taped flat to the skin. This point is not on any acupuncture meridian or point.
Study: NCT05391906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Description: Diffusion-weighted magnetic resonance imaging
Study: NCT04748614

Intervention type: OTHER
Intervention: Cost
Description: ICU cost

Intervention type: OTHER
Intervention: Cost
Description: ICU cost
Study: NCT05601167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines' validated at the time of the study
Study: NCT06585761

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: patients with HF are subjected to regular dose of SGLT2I member according to patient status.

Intervention type: DEVICE
Intervention: echo cardiogram
Description: the patients are subjected to ECHO to determine their EF prior to and post the study

Intervention type: DEVICE
Intervention: echo cardiogram
Description: the patients are subjected to ECHO to determine their EF prior to and post the study
Study: NCT06536569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal limiting membrane (ILM) Peeling with Sharkskin Forceps
Description: 25g Grieshaber Sharkskin ILM Forceps with Reflex Handle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal limiting membrane (ILM) Peeling with Standard Forceps
Description: 25g Grieshaber Standard ILM Forceps
Study: NCT04759352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-test genetic counseling delivered by telephone
Description: Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
Study: NCT05156957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapeutic intervention
Description: The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.